These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 28071970)

  • 1. The making of bispecific antibodies.
    Brinkmann U; Kontermann RE
    MAbs; 2017; 9(2):182-212. PubMed ID: 28071970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
    Klein C; Sustmann C; Thomas M; Stubenrauch K; Croasdale R; Schanzer J; Brinkmann U; Kettenberger H; Regula JT; Schaefer W
    MAbs; 2012; 4(6):653-63. PubMed ID: 22925968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The manufacturing considerations of bispecific antibodies.
    Underwood DJ; Bettencourt J; Jawad Z
    Expert Opin Biol Ther; 2022 Aug; 22(8):1043-1065. PubMed ID: 35771976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats.
    Madsen AV; Kristensen P; Buell AK; Goletz S
    MAbs; 2023; 15(1):2189432. PubMed ID: 36939220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
    Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
    MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
    Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
    MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.